NCT04195958终止4 期
A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 12
- 主要终点
- Change From Baseline at Week 24 in Endurance Time (Minutes) During Cardiopulmonary Exercise Testing (CPET) at a Constant Work Rate (CWR)
研究概览
简要总结
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up. Approximately 60 participants will be enrolled, and omalizumab will be dosed according to the approved United States Package Insert (USPI) dosing table.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Physician-diagnosed asthma for at least 12 months prior to screening
- •Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen
- •Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period
- •Able to safely complete incremental exercise tolerance at screening
- •Pre-bronchodilator FEV1 of 40%-80% of predicted at screening
- •Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry
- •On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (≥)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for ≥3 months prior to screening
- •Uncontrolled asthma during the screening period, defined as an ACQ-5 ≥0.75 score
- •Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug.
排除标准
- •Known history of anaphylaxis/hypersensitivity to omalizumab
- •Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening
- •Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening
- •Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period
- •Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period
- •Isolated diagnosis of exercise induced asthma without chronic symptoms
- •History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma
- •Current malignancy or history of malignancy within 5 years prior to screening
- •Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions
- •Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening
- •Current smoker or past smoker with >10 pack years
- •Known HIV infection at screening
- •Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening
- •Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening
- •Active tuberculosis requiring treatment within 12 months prior to screening
- •History of alcohol, drug, or chemical abuse within 6 months of screening
研究组 & 干预措施
Omalizumab
Experimental
干预措施: Omalizumab (Drug)
结局指标
主要结局
Change From Baseline at Week 24 in Endurance Time (Minutes) During Cardiopulmonary Exercise Testing (CPET) at a Constant Work Rate (CWR)
时间窗: From Baseline to Week 24
This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
次要结局
- Percentage of Participants With Adverse Events Leading to Discontinuation of Omalizumab(From Baseline to Week 24)
- Percentage of Participants With Adverse Events(From Baseline to Week 28)
- Change From Baseline at Week 24 in Physical Activity (Minutes/Day) as Assessed by a Wearable Physical Activity and Sleep Monitor(From Baseline to Week 24)
- Change From Baseline at Week 24 in Sleep Efficiency as Assessed by a Wearable Physical Activity and Sleep Monitor(From Baseline to Week 24)
- Percentage of Participants With Serious Adverse Events(From Baseline to Week 28)
- Change From Baseline at Week 24 in Dynamic Hyperinflation at Isotime, as Measured by Inspiratory Capacity During CPET at a CWR(From Baseline to Week 24)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
4 期
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate AsthmaAsthmaNCT00546143Novartis32
已完成
3 期
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 TherapyPersistent Allergic AsthmaNCT01202903Novartis Pharmaceuticals616
已完成
3 期
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsNasal PolypsChronic RhinosinusitisNCT03280550Hoffmann-La Roche138
已完成
3 期
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal PolypsNasal PolypsChronic RhinosinusitisNCT03280537Hoffmann-La Roche127
已完成
3 期
Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsSeasonal Allergic RhinitisNCT03369704Novartis Pharmaceuticals337